WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
MacKinnon versus Hellebuyck highlight firstCoachella 2024: Photo highlights as weekend 2 gets underwayRuins of 3,000Yankees' Cortes learns pump fake pitch is actually illegal; pitches seven innings vs. RaysAlison Hammond, 49, and new Russian boyfriend David Putman, 26, look lovedMy 'sinus infection' turned out to be a one in a million nasal cancer at just 28Rumer Willis celebrates daughter Louetta's first birthday with heartYankees' slugger Aaron Judge strikes out four times, hears boos on promotional bobblehead dayMeet the man exposing NYC's tollUnprecedented wave of narco